NEW YORK, Sept. 16, 2016 -- Barrack, Rodos & Bacine is investigating the Board of Directors of Standex International Corp. (“Standex” or the “Company”) for possible violations of securities laws and Delaware law relating to the Proxy Statement the Company filed concerning the upcoming annual shareholder meeting to be held on October 27, 2016.
The Proxy Statement filed by Standex with the U.S. Securities and Exchange Commission on September 9, 2016 recommends that Standex shareholders vote to approve five Company proposals. Barrack, Rodos & Bacine’s investigation of these Company proposals indicates that they may contain misleading information that will inhibit a meaningful stockholder vote.
Holders of Standex stock are encouraged to contact Michael Toomey of Barrack Rodos & Bacine, at the following toll-free number: 877-386-3304, or via e-mail to [email protected].
Barrack Rodos & Bacine has more than three decades of experience prosecuting securities and corporation law actions, and has achieved some of the largest recoveries in the history of such litigation.
Michael Toomey 877-386-3304 [email protected]


SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel
Samsung Shares Drop as Labor Union Confirms Planned Strike
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks
TrumpRx Expands Discount Drug Access With 600 Generic Medications
Standard Chartered Targets Higher Profitability With Major Workforce Cuts
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 



